Skip to main content
PTHS
NYSE Life Sciences

Pelthos 10-Q Discloses Unremediated Material Weakness and Restatement Alongside Q3 Results

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$9.39
Mkt Cap
$36.92M
52W Low
$8.72
52W High
$37.4
52W Position info
7.7% above low
Off High info
75% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

PTHS is trading near its 52-week low of $8.72 (7.7% above the low).

Summary

Pelthos' Q3 10-Q shows Zelsuvmi revenue doubling to $15.2 million and the net loss narrowing to $7.9 million, but also discloses an unremediated material weakness in convertible-note fair-value accounting that forced a restatement of Q1 2026.


Key Events · Earnings and Guidance · PTHS

  • Material Weakness Disclosed, Still Unremediated

    Management concluded internal control over financial reporting was not effective as of September 30, 2026 due to a misapplication of ASC 820 on the November 2025 convertible notes; the weakness has not been remediated.

  • Q1 2026 Financials Restated

    The March 31, 2026 quarter was restated via a 10-Q/A filed August 13, 2026, and disclosure controls were also deemed not effective at September 30, 2026.

  • Zelsuvmi Revenue Doubles, Loss Narrows

    Q3 net product revenue was $15.2 million versus $7.1 million a year earlier; net loss fell to $7.9 million from $23.4 million in Q2 2026, while the nine-month loss was $56.4 million.

  • Runway Rests on Zelsuvmi, Not the Merger

    $17.7 million of cash at September 30 plus the $10.0 million drawn October 30, 2026 is projected to fund a year of operations; management excluded the Castle Creek merger and $57.5 million PIPE from that going-concern conclusion.


Analysis · PTHS · Life Sciences

The earnings numbers were already out this morning, but the 10-Q carries the more consequential news: management says its internal control over financial reporting was not effective at September 30, 2026 because of a misapplication of ASC 820 fair-value guidance on the November 2025 convertible notes, which forced a restatement of the March 31, 2026 quarter. That weakness remains unremediated — the company swapped valuation firms in Q3 but has not closed the gap. The operating story, by contrast, is improving: Zelsuvmi revenue of $15.2 million in Q3 versus $7.1 million a year ago, and the net loss narrowed to $7.9 million from $23.4 million in Q2. Cash of $17.7 million plus the $10.0 million drawn on October 30, 2026 is enough for twelve months, but only on the company's own sales forecast — and management explicitly did not count the Castle Creek merger or the $57.5 million PIPE in that math, so the runway conclusion rests on Zelsuvmi alone. Note the $9.3 million nine-month hit from remeasuring the convertible notes is a non-cash mark-to-market swing, not new dilution or cash out the door.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PTHS was trading at $9.39 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.9M. The 52-week trading range was $8.72 to $37.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PTHS - Latest Insights

PTHS
Nov 12, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.39
Real-time Price: $9.39 info
Change: $0 (0%) info
Market Cap: $36.92M info
PTHS
Nov 03, 2026, 8:20 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $10.78
Real-time Price: $9.39 info
Change: -$1.39 (-13%) info
Market Cap: $36.92M info
PTHS
Oct 30, 2026, 9:20 AM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $19.86
Real-time Price: $9.39 info
Change: -$10.47 (-53%) info
Market Cap: $36.92M info
PTHS
Oct 30, 2026, 9:17 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $20.00
Real-time Price: $9.39 info
Change: -$10.61 (-53%) info
Market Cap: $36.92M info